Design and dosimetric considerations of a modified COMS plaque: The reusable "seed-guide" insert

Medical Physics

Volumn 32, Issue 8, 2005, Pages 2706-2716

  Astrahan, Melvin A ^a   Szechter, Andrzej ^b   Finger, Paul T ^c,d  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b Saint Vincents Comprehensive Cancer Center   (United States)

^c ST VINCENT S COMPREHENSIVE CANCER CENTER   (United States)

^d NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Dosimetry; Eye plaque; Gold; I 125; Pd 103; Seed carrier; Silastic

Indexed keywords

ATOMS; DENTAL ALLOYS; GLUES; GLUING; GOLD; GOLD ALLOYS;

ATOMIC COMPOSITIONS; COLLABORATIVE OCULAR MELANOMA STUDIES; DOSE DISTRIBUTIONS; EFFECTIVE ATOMIC NUMBER; EYE PLAQUE; SILASTIC; SILASTIC SEED CARRIERS; UNINTENDED CONSEQUENCES;

DOSIMETRY;

ACRYLIC ACID; ADHESIVE AGENT; CYANOACRYLATE; GOLD ALLOY; IODINE 125; PALLADIUM 103; SILASTIC; WATER;

ARTICLE; DOSIMETRY; INSTRUMENT STERILIZATION; MELANOMA; MODEL; PRIORITY JOURNAL; RADIATION DOSE DISTRIBUTION; RADIATION ENERGY; RADIATION MEASUREMENT; X RAY FLUORESCENCE;

EID: 23944512137     PISSN: 00942405     EISSN: None     Source Type: Journal    
DOI: 10.1118/1.1993828     Document Type: Article

References (28)

1. Collaborative Ocular Melanoma Study Group, "The COMS randomized trial of iodine 125 brachytherapy for choroidal melanoma. III. Initial mortality findings. COMS Report No. 18," Arch. Ophthalmol. (Chicago) 119, 969-982 (2001).
2. R. W. Kline and P. D. Yeakel, "Ocular melanoma, I-125 plaques," Med. Phys. 14, 475 (1987).
3. M. Astrahan, G. Luxton, G. Jozsef, T. D. Kampp, P. Liggett, and M. D. Sapozink, "An interactive treatment planning system for ophthalmic plaque radiotherapy," Int. J. Radiat. Oncol., Biol., Phys. 18, 679-687 (1990).
4. S-T. Chiu-Tsao, L. L. Anderson, K. O'Brien, L. Stabile, and J. C. Liu, "Dosimetry for 125I seed (model 6711) in eye plaques," Med. Phys. 20, 383-389 (1993).
5. 125I seed eye plaque dose distribution including penumbra characteristics," Med. Phys. 23, 407-418 (1996).
6. M. A. Astrahan, "Improved treatment planning for COMS eye plaques," Int. J. Radiat. Oncol., Biol., Phys. 61, 1227-1242 (2005).
7. A. Wu and F. Krasin, "Film dosimetry analyses on the effect of gold shielding for Iodine-125 eye plaque therapy for choroidal melanoma," Med. Phys. 17, 843-846 (1990).
8. Collaborative Ocular Melanoma Study Group, COMS Manual of Procedures (National Technical Information Service, Springfield, VA, 1995), Chap. 12. Version 2/99, PB95-179693.
9. R. Nath, L. L. Anderson, G. Luxton, K. A. Weaver, J. F. Williamson, and A. S. Meigooni, "Dosimetry of interstitial brachytherapy sources: Recommendations of the AAPM Radiation Therapy Committee Task Group No. 43," Med. Phys. 24, 209-234 (1995).
10. M. J. Rivard, B. M. Coursey, L. A. DeWerd, W. F. Hanson, M. S. Huq, G. S. Ibbott, M. G. Mitch, R. Nath, and J. F. Williamson, "Update of AAPM task Group No. 43 Report: A revised AAPM protocol for brachytherapy dose calculations," Med. Phys. 31, 633-674 (2004).
11. P. T. Finger, D. F. Lu, A. Buffa, D. S. De Blasio, and J. L. Bosworth, "Palladium-103 versus iodine-125 for ophthalmic plaque radiotherapy," Int. J. Radiat. Oncol., Biol., Phys. 27, 849-854 (1993).
12. R K. Lommatzsch "Treatment of choroidal melanomas with Ru-106/Rh-106 beta ray applicators," Surv. Ophthalmol. 19, 85-100 (1974).
13. G. Luxton, M. A. Astrahan, P. Liggett, D. L. Neblett, D. M. Cohen, and Z. Petrovich, "Dosimetric calculations and measurements of gold plaque ophthalmic irradiators using Iridium-192 and Iodine-125 seeds," Int. J. Radiat. Oncol., Biol., Phys. 15, 167-176 (1988).
14. M. A. Astrahan, G. Luxton, Q. Pu, and Z. Petrovich, "Conformal episcleral plaque therapy," Int. J. Radiat. Oncol., Biol., Phys. 39, 505-519 (1997).
15. 125I brachytherapy," Int. J. Radiat. Oncol., Biol., Phys. 56, 1373-1380 (2003).
16. M. Astrahan, G. Luxton, G. Jozsef, P. Liggett, and Z. Petrovich, "Optimization of I-125 ophthalmic plaque brachytherapy," Med. Phys. 17, 1053-1057 (1990).
17. M. D. C. Evans, M. A. Astrahan, and R. Bate, "Tumor localization using fundus view photography for episcleral plaque therapy," Med. Phys. 20, 769-775 (1993).
18. S. Knutsen, R. Hafslund, O. R. Monge, H. Valen, L. P. Muren, B. L. Rekstad, J. Krohn, and O. Dahl, "Domestric verification of a dedicated 3D treatment planning system for episcleral plaque therapy," Int. J. Radiat. Oncol., Biol., Phys. 51, 1159-1166 (2001).
19. K. Packer, "Verification of ophthalmic brachytherapy treatment planning," Australian Physical & Engineering Sciences in Medicine 24, 177-180 (2001).
20. A. L. Krintz, W. F. Hanson, G. S. Ibbott, and D. S. Followill, "A reanalysis of the collaborative ocular melanoma study medium tumor trial eye plaque dosimetry," Int. J. Radiat. Oncol., Biol., Phys. 56, 889-898 (2003).
21. M. A. Astrahan, "A patch source model for treatment planning of ruthenium ophthalmic applicators," Med. Phys. 30, 1219-1228 (2003).
22. 125I for ophthalmic plaque dosimetry," Med. Phys. 15, 397-400 (1988).
23. P. T. Finger, J. Romero, R. Rosen, R. Iezzi, R. Emery, and T. Berson, "3-dimensional ultrasound for choroidal melanoma: Localization of radioactive eye-plaques," Arch. Ophthalmol. (Chicago) 116, 305-312 (1998).
24. 125I seed at close range," Med. Phys. 15, 627-628 (1988).
25. 123I seed," Med. Phys. 17, 172-178 (1990).
26. 125I seeds," Med. Phys. 20, 1251-1256 (1993).
27. P. T. Finger, A. Berson, T. Ng, and A. Szechter, "Palladium-103 plaque radiotherapy for choroidal melanoma: an 11-year study," Int. J. Radiat. Oncol., Biol., Phys. 54, 1438-1445 (2002).
28. D. Flühs, G. Anastassiou, J. Wening, W. Sauerwein, and N. Bornfeld, "The design and the dosimetry of bi-nuclide radioactive ophthalmic applicators," Med. Phys. 31, 1481-1488 (2004).